|
|
|
|
|
|
|
|
"Arrayit's OvaDx(R), the market's first comprehensive diagnostic screening test for ovarian cancer, uses approximately 100 proteomic biomarkers to identify molecular beacons of ovarian cancer that accumulate in the bloodstream as soon as an ovarian tumor begins to develop. OvaDx(R) detects both early and late stage ovarian cancer with high sensitivity and specificity using Arrayit's proprietary microarrays, which are tiny medical devices that screen large numbers of patient samples in a highly miniaturized and automated manner. OvaDx(R) leverages Arrayit's patented manufacturing technology and will be marketed and sold upon FDA approval by the company's subsidiary Arrayit Diagnostics, Inc."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.